Key Drivers
- Strong margins
- Solid liquidity
- Premium valuation
AIAI Summary
Danaher remains a high-quality cash-generating business, but with core growth still sluggish and Masimo adding leverage/integration risk, the stock now looks like a “prove-it” story where upside depends on reaccelerating organic growth and disciplined deal execution rather than premium multiple expansion.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong margins
- •Solid liquidity
- •Premium valuation
DHR combines strong profitability, solid cash generation, and manageable leverage, but its premium valuation and low tangible equity suggest limited near-term upside.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support failure
- •Weak momentum
DHR remains in a short-term downtrend, with lower highs/lower lows and failed support in the $171-$175 zone leaving it vulnerable unless it reclaims that area.
Sharp decline from $194.75 on 2026-04-17 to $161.91 on 2026-05-15 signals sustained selling pressure
Sentiment & News
Key News Insights:
- •EPS beat
- •Raised outlook
- •Diagnostics weakness
Danaher beat Q1 EPS expectations and raised 2026 guidance, but mixed segment performance, FX/cost pressures, and a shareholder settlement tempered the otherwise constructive outlook.
Positive earnings momentum and higher guidance support the stock, but uneven execution and legal overhang may limit near-term upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings